Health Insurer Stocks: Recent Crash is Likely An Attractive Buffett Style "Fat Pitch" Opportunity

Personal Note I thank everyone for their patience this week. I was stuck in South Carolina (Connor’s Wedding) for 2 extra days due to the worst winter storms in decades, and then came home to learn my father had emergency eye surgery for retinal detachment. I have 3 meetings today (catching up) and 2 doctor’s visits (including a post-surgery follow-up), so today’s article is a special report that some GNG members asked for. Something that I believe can be delivered with high quality within the few hours I have before I have to take care of all this. There is so much to catch up on (including in the weekly Economic/Market Valuations/Earnings) report that this is the best I can do on this single topic. Thank you for your patience and understanding. Big (and Bad) Day For Health Insurance Stocks On Tuesday This is What Political Risk Looks Like Source: DailyChartBook Last year, Medicare raised reimbursement rates by almost 6%, and that was the expectation from the analyst consensus (based on management guidance) this year. The difference of 5% in rates will (if implemented) mean a significant impact on revenue and profits, but does that justify up to 26% losses in certain health insurers like Humana? Source: Ycharts At the bottom of this article is the full deep dive from the AI research team. Step 1: Go to FactSet Terminal and download all consensus estimates for HUM, ELV, CVS, and UNH. Step 2: Take those and Morningstar’s data and combine them with FactSet’s. (Over $1,500 per month is what this data alone costs. Step 3: Feed into Gemini 3 Pro Deep Research to create as comprehensive a report (from an investor’s perspective). Featuring over 200 reputable sources. Step 4: feed that report (and all the data) into Chat GPT 5.2 Pro Deep Research with instructions to fact-check everything and create a final, complete deep dive report. Starting with a 2-sentence summary, then a 10-bullet point TLDR summary, and then the summary charts and tables. And then the final deep dive report (for anyone who wants to read through all the details). The report will include industry AND individual company analysis (that would normally take me an entire week to provide at the expense of doing nothing else). And meanwhile, I’ll provide my thoughts after manually updating all the FAST Graphs charts to show what the historical PE vs AVG PE shows, and also the Morningstar fair value estimates (have the fair value PEs fallen? If so, by how much)? Normally, my tag team reports also include PEGY analysis; however, since 2 of these companies haven’t yet reported earnings, analysts will likely hold off on adjusting their estimates until management provides guidance after earnings. Also, that would take a few additional hours that I don’t have today. Expert Human Analysis Morningstar Summary: A Likely Overreaction And Buying Opportunity Source: Morningstar Morningstar expects no significant change in fair values because it thinks this is a single year’s decision (possibly politically motivated ahead of the 2026 midterm election) and therefore won’t affect long-term growth estimates. FAST Graphs Analysis (Both Historical & Morningstar Estimates) UnitedHealth Medium-Term Outlook Looks Great (Even though the valuation opportunity isn’t close to the one in 2026) Source: FAST Graphs, FactSet 5 Year Consensus Outlook: 30% Upside This Year And 169% Upside Potential Over 5 Years Source: FAST Graphs, FactSet Buffett-like return potential from UNH over the next 1 to 5 years. Unless my research team comes up with some really shocking bad news on UNH, I think this is a buying opportunity. Morningstar Fair Value PE 26.1 Source: FAST Graphs, FactSet Morningstar’s fair value PE of 26 would indicate a much better opportunity, up to 33% CAGR justified by fundamentals over the next 3 years, (assuming the acceleration in growth management is guiding for what happens). Morningstar Fair Value PE